• Product NameDabrafenib (GSK2118436)
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityDabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
• Target NameRaf inhibitor
• CAS No. 1195765-45-7
• Calculated MW 519.56
• Formulation C23H20F3N5O2S2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
  Pathways:MAPK
  Receptor:B-Raf; B-Raf (V600E); C-Raf
  Boling pt:
  Melting pt:
  Solubility:DMSO: 30 mg/mL (57.74 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Sylvie Laquerre, et al. 2009, EORTC International Conference. Abst B88.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting